New Pharmacotherapies for Pulmonary Hypertension: Where Do They Fit in?
- 11 October 2014
- journal article
- review article
- Published by Springer Nature in Current Hypertension Reports
- Vol. 16 (12)
Abstract
Pulmonary arterial hypertension (PAH) is a rare, progressively worsening disease characterized by dysfunction among endothelial and smooth muscle cells within the pulmonary vasculature with a resultant increase in pulmonary vascular resistance, right ventricular maladaptation and failure, and ultimately early death. The three major therapeutic classes of medications available to treat PAH act as either prostacyclin analogs or endothelin receptor antagonists (ERAs) or by increasing local nitric oxide (NO) levels by means of phosphodiesterase type 5 inhibitors. Several recent trials have investigated the use of oral prostanoid therapy, next-generation ERAs, and soluble guanylate cyclase stimulators (to increase NO levels) as well as novel formulations of pre-existing therapies. The goal of this manuscript is to briefly review established therapies and then discuss recent developments and practical considerations in each of the major drug classes.Keywords
This publication has 47 references indexed in Scilit:
- Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized studyAmerican Heart Journal, 2014
- EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertensionAmerican Heart Journal, 2014
- Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)Advances in Therapy, 2013
- Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin TherapiesThe American Journal of Cardiology, 2013
- Current therapeutics and practical management strategies for pulmonary arterial hypertensionAmerican Heart Journal, 2011
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJACC, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled TrialAmerican Journal of Respiratory and Critical Care Medicine, 2002
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996